

Scheme of Synthesis




Table 1: Physical Characteristics of Synthesized Compounds

Compound code	R	R ₁	Molecular Formula	Weight(g/mol)	Melting Point (°C)	Yield (% w/w)	R _f Value
4a	H	-OC ₂ H ₅	C ₁₄ H ₁₆ N ₂ O ₃	260.28	198-202	80.00	0.57
4b	Cl	-OC ₂ H ₅	C ₁₄ H ₁₅ N ₂ O ₃ Cl	294.73	210-214	73.00	0.60
5a	H	-OH	C ₁₂ H ₁₂ N ₂ O ₃	232.23	198-202	49.00	0.33
5b	Cl	-OH	C ₁₂ H ₁₁ N ₂ O ₃ Cl	266.68	166-170	42.00	0.36
6a	H	-N(CH ₃) ₂	C ₁₆ H ₁₇ N ₃ O ₂	259.30	176-180	73.78	0.65
6b	H	-N(C ₂ H ₅) ₂	C ₁₆ H ₂₁ N ₃ O ₂	287.35	180-184	70.54	0.62
6c	H	-(4-morpholinyl)	C ₁₇ H ₂₁ N ₃ O ₂	301.34	170-174	65.00	0.55
6d	H	-piperidinyl	C ₁₄ H ₁₆ N ₂ O ₃	299.36	168-172	68.50	0.53
6e	Cl	-N(CH ₃) ₂	C ₁₆ H ₁₆ N ₃ O ₂ Cl	294.9	190-194	67.00	0.64
6f	Cl	-N(C ₂ H ₅) ₂	C ₁₆ H ₂₀ N ₃ O ₂ Cl	321.80	194-198	65.00	0.60
6g	Cl	-(4-morpholinyl)	C ₁₆ H ₁₈ N ₃ O ₃ Cl	335.78	176-180	55.00	0.58

Biological Evolution

Pharmacological evaluation is a crucial thing to ensure the activity of the compounds. In this era, the prevalence of heart diseases has increased to a great extent. Antihypertensive agents are among the most commonly used to treat the variety of heart diseases. Literature review revealed that substituted dihydropyrimidine containing compounds show different biological activities. These compounds are also evaluated for their antihypertensive activity, calcium channel blocking activity.

Measurement of Antihypertensive activity

Purpose and rationale

There are various in-vivo and in-vitro methods are available for evaluation of antihypertensive activity. Antihypertensive activity was performed by in-vitro method in which effect of test compounds on blood pressure is measured. (Naik et al., 2007).

Procedure

Heparin at the dose of 2000 IU/ kg by I.V. route has been administered to rats of either sex. Rats of either sex have been anaesthetized with Pentothal sodium 80 mg/kg given

by intraperitoneally. Blood pressure transducer was calibrated initially by using of mercury manometer. For each rat, the carotid artery was cannulated and attached to blood pressure transducer to record the initial arterial blood pressure which will be calibrated initially by using of mercury manometer. In the similar way on the opposite side, the jugular vein was cannulated to administer 0.3ml heparinised saline for checking normal flow of fluid in the vein then the different doses of test samples were used to measure the effect on blood pressure by inhibition of adrenaline response. (Humble et al., 2008). Calcium antagonism in the isolated rat ileum Purpose and rationale Contraction of ileum was induced by adding potassium chloride & calcium chloride to the organ bath containing slightly modified Tyrode solution (NaCl=8.0gm/l, KCl=0.2gm/l, CaCl₂=0.18gm/l, NaH₂PO₄=0.1gm/l, MgCl₂=0.1gm/l, Glucose=1.0gm/l, NaHCO₃=1.0gm/l). Test drugs with calcium channel blocking activity have a relaxing effect (Mohamed et al., 2007). Procedure The assembly was being set up and arrangement was made for experiment. The animal kept for overnight fasting was stunned by a sharp blow on head the head and sacrificed by cutting neck blood vessels. The abdominal cavity was quickly opened and a piece of ileum was isolated. It was placed in a petridish containing tyroide solution maintained at 37°C. The

mesentery of ileum was removed and the interior content was washed by blowing Tyrode solution (NaCl=8.0gm/l, KCl=0.2gm/l, CaCl₂=0.18gm/l, NaH₂PO₄=0.1gm/l, MgCl₂=0.1gm/l, Glucose=1.0gm/l, NaHCO₃=1.0gm/l) with help of pipette. The tissue was mounted in mammalian organ bath and connected to isotonic frontal writing lever. The tissue was allowed to stabilize for 30min. The responses of acetylcholine were taken till the maximum effect was obtained. The normal Tyrode solution was changed with Tyrode containing test solution. The responses of acetylcholine were taken with same dose and continued till maximum effect obtained. The percentage of relaxation from the test-drug, precontracted level was calculated for each concentration of test compound. An IC₅₀ was calculated by linear regression analysis:

$$y = 96.18x + 1.372$$




Table 2: Spectral data of synthesized compounds

Compound code	UV(λ_{max} , nm)	IR (ν , cm^{-1})	Mass (m/z)	NMR (δ , ppm)
		3290 (-NH), 1691,		
4a	285	1680 (-C=O) 1427 (-CH ₃ deformation), 1280 (C-O)	260.9 [M ⁺]	
5a	256	3184 (-NH), 1680 (-C=O) 1400 (-CH ₃ deformation), 1244 (C-O), 3000-3400 (OH) 3221 (-NH), 1691	232 [M ⁺], 218 [M CH ₃]	
6a	387	1680 (-C=O) 1427 (-CH ₃ deformation), 1552 (C=C Ph), 1280 (C-O)	259 [M ⁺]	
6b	380	3269 (-NH), 1677, 1690 (-C=O) 1440 (-CH ₃ deformation), 1552 (C=C Ph)	288.9 [M ⁺]	7.2-8.2(m, 6H, ArH), 5.4 (d, 1H NH), 5.9 (s, 1H, NH), 1.15 (t, 6H CH ₃), 4.0 (q, 4H, NH), 2.3(s, 3H CH ₃)
6c	389	3100 (-NH), 1689 (-C=O) 3240 (-NH), 1677,	301.4 [M ⁺]	
6d	366	1652 (-C=O) 1427 (-CH ₃ deformation),	299.3 [M ⁺]	
6e	282	C-Cl (825.33), C=O (1685, 1634), -CH ₃ deformation (1488), C-N (1226), NH (3190, 3224)	294.8 [M ⁺]	
6f	270	C-Cl (829.33), C=O (1667, 1647), -CH ₃ deformation (1488), C-N (1226), NH (3139)	322.8 [M ⁺]	
6g	272	C-Cl (829.33), C=O (1674), -CH ₃ deformation (1474), C-N (1234), NH (3097, 3217)	335.7 [M ⁺]	7.4-7.8 (m, 5H, ArH), 6.2 (s, 2H, NH), 1.2 (s, 3H, CH ₃), 1.4-2.4 (m, 10H, CH ₂)
6h	280	C-Cl (825), C=O (1647, 1700), -CH ₃ deformation (1488), C-O (1226), NH (3251)	333.8 [M ⁺]	

Table: 3 Screening of Antihypertensive activity

Compound code	Dose (ml)	Control (mm Hg) (h)	Test (mm Hg) (h)	% Inhibition in blood pressure
Nifedipine	0.3	29.17	20.00	31.44
	0.3	28.34	20.84	26.46
6a	0.3	29.17	24.17	17.14
	0.3	30.00	23.34	22.20
6b	0.3	27.50	21.67	21.20
	0.3	29.17	22.50	22.87
6c	0.3	29.17	20.00	31.44
	0.3	30.00	21.67	27.77
6d	0.3	29.17	25.00	14.30
	0.3	29.17	25.84	11.16
6e	0.3	29.17	24.17	17.14
	0.3	29.17	23.84	18.27
6f	0.3	28.34	22.50	20.61
	0.3	27.50	24.17	12.10
6g	0.3	28.34	22.50	20.61
	0.3	28.34	24.17	14.71
6h	0.3	28.34	25.00	11.79
	0.3	27.50	22.50	17.14

Table: 4 Screening of Calcium Channel Blocking activity of Nifedipine

Compound	Dose (ml)	Control (cm) (h)	Test (cm) (h)	% Inhibition	IC ₅₀ ($\mu\text{g/ml}$)
Nifedipine	0.1	3.4	3.0	11.76	20
	0.2	3.4	2.7	20.58	
	0.3	3.4	2.3	32.35	
	0.4	3.3	2.1	35.29	
	0.5	3.3	1.7	48.48	
	0.6	3.3	1.2	61.76	

4. Results and Discussion

All the eight synthesized compounds (6a-6h) were screened for antihypertensive and calcium channel blocking activity. Nifedipine was used as standard reference drug for screening of antihypertensive and calcium channel blocker because nifedipine and test compounds both have similar bioisosteric nucleus. In the test samples (dihydropyrimidine ring) there

are two nitrogen (N) atoms which is bioisosteric with (CH) and one methyl group (CH₃) which is bioisosteric with ketone (C=O) of nifedipine (dihydropyridine ring). The ester (-COO-) linkage of nifedipine has been replaced by amide (-CONH-) linkage in the test compounds.





Table: 5 Screening of Calcium Channel Blocking activity

Compound code	Dose (ml)	Control (cm) (H)	Test (cm) (h)	% Inhibition	IC ₅₀
6a	0.1	3.3	3.0	9.09	22
	0.3	3.3	2.3	30.30	
	0.5	3.4	1.9	44.12	
6b	0.1	3.4	3.1	8.82	36.54
	0.3	3.4	2.5	26.47	
	0.5	3.3	2.4	27.72	
6c	0.1	3.3	3.1	6.06	21.06
	0.3	3.3	2.4	27.27	
	0.5	3.3	1.9	42.43	
6d	0.1	3.3	3.0	9.09	22
	0.3	3.4	2.1	38.23	
	0.5	3.3	2.0	41.18	
6e	0.1	3.4	3.0	11.76	21.10
	0.3	3.4	2.8	17.65	
	0.5	3.3	1.7	48.48	
6f	0.1	3.4	2.8	17.64	19.76
	0.3	3.4	2.2	35.29	
	0.5	3.4	1.7	50.00	
6g	0.1	3.4	2.5	26.47	28.99
	0.3	3.3	2.3	30.30	
	0.5	3.3	1.9	42.42	
6h	0.1	3.4	3.0	11.76	24.26
	0.3	3.4	2.4	29.41	
	0.5	3.4	2.0	41.18	

Compound 6c was found to have better antihypertensive activity and compound 6f found to have better calcium channel blocker activity.



6c: 6-methyl-5-(morpholin-4-ylcarbonyl)-4-phenyl-3,4-dihydropyrimidin-2(1H)-one (logP=0.8).

6f: 4-(4-chlorophenyl)-N,N-diethyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (logP=2.80).

Acknowledgement

The authors are thankful to the Department of Pharmacy Guru Ghasidas Vishwavidyalaya Bilaspur Chhattisgarh for UV and FTIR spectras, Massspectras Panjab University, Chandigarh for NMR spectras.

References

[1] Atwal KS, George CR, David K, David MF, Suzzane M, Swanson BN, Joseph S, Smillie KM. Dihydropyrimidine calcium channel blockers: 2, 3- substituted -4- aryl- 1, 4-dihydro -6- methyl -5- pyrimidine carboxylic acid esters as potent mimics of dihydropyridines. J Med Chem1990; 30: 2625-2635.

[2] Atwal KS, George CR, David K, David MF, Suzzane M, Anders H, Malley FM, David MF. Dihydropyrimidine calcium channel blockers:2-heterosubstituted-4-aryl-1, 4-dihydro-6-methyl-5-pyrimidine carboxylic esters as potent mimics of dihydropyridines. J Med Chem 1990; 33:1510-1515.

[3] Chhabria MT, Bhatt HG, Raval HG, Oza PM. Synthesis and biological evaluation of some 5-ethoxy carbonyl-6-isopropylamino-4- (substituted phenyl) aminopyrimidines as potent analgesic and anti inflammatory agent, Biorg Med Chem 2007; 17: 1022-1024.

[4] Heda LC, Sharma R, Pareek C, Chaudhari PB. Synthesis and antimicrobial activity of some derivatives of 5-substituted indole dihydropyrimidines, E-J Chem 2009; 6(3): 770-774.

[5] Humle R. Cyanamide a convenient building block to synthesis 4-aryl-2-cyanoimino-3, 4-dihydro-1H-pyrimidine system via multicomponentreaction Tetrahedron 2008; 64: 3372-3380.

[6] Kumar B. Kaur B., Kaur J. Thermal/microwave assisted synthesis of substituted tetrahydropyrimidines as potent calcium channel blockers. Indian J Chem 2002; 41(B): 1526-1530.

[7] Mishra R, Kumar BM, Harinarayan M. Synthesis and antimicrobial evaluation of some 3, 4-dihydropyrimidine-2-one deri. Applied Sci Res 2008; 3(2): 203-208.

[8] Mohamed NR, El-Saidi M.M.T., Ali Y.M., Elnagdi M.H.. Utility of 6-amino-2-thiouracil as a precursor for the synthesis of bioactive pyrimidine derivatives, Bioorganic and Medicinal Chem 2007; 15: 6227- 6235.

[9] Naik TA, and Chikhalia KH. Studies on synthesis of pyrimidine derivatives and their pharmacological evaluation, E Journal of Chemistry 2007; 4(1): 60-66.

[10] Pathak P, Kaur R, Kaur B. microwave assisted synthesis of some novel 1, 4-dihydropyrimidine derivatives of biological interest, Artivoc 2006; 16: 160-167.

[11] Patil PA, Hole RP, Chikhale RV, Bhusai KP. Synthesis of 3, 4- dihydropyrimidine-2(1H)-one derivatives using for their biological screening. Int J Chem Tech Res 2009; 1(2): 373-384.

[12] Purohit MN, Bhavya K, Pujar GV. Synthesis and antibacterial activity of 5-(5'-substituted-1, 3, 4-oxadiazol-2'-yl) dihydropyrimidinone derivatives J Pharm Chem 2009; 3: 1-3.

[13] Ravikumar K Sridhar B. Two carbamoyl substituted dihydropyrimidines potent mimics of dihydropyridine calcium channel blockers Acta Cryst. 2005; C61(1): 41-44.

[14] Rovnyak GC, Atwal KS, Hedberg A, Kimball DS, Moreland S, Gougoulas Z.I. dihydropyrimidine calcium channel blockers 4-basic 3-substituted-4-aryl-1, 4-dihydropyrimidine-5-carboxylic acid ester as potentantihypertensive agent J Med Chem 1992; 35: 3254-3263.

[15] Singh BK, Mishra M, Saxena N, Yadav G P, Maulik P R, SahooM K, Gaur R L, Murthy, Tripathi R P. Synthesis of 2-sulfanyl-6-methyl-1, 4-dihydropyrimidine as a new class of antifilarial agent Eur J Med Chem2008; 43(12): 2717-2723.